Silverarc Capital Management LLC Trims Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Silverarc Capital Management LLC trimmed its position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 37.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,486,709 shares of the company's stock after selling 1,513,291 shares during the quarter. Silverarc Capital Management LLC owned about 2.40% of Unicycive Therapeutics worth $1,975,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in UNCY. Vivo Capital LLC lifted its position in Unicycive Therapeutics by 123.0% during the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock valued at $7,918,000 after purchasing an additional 5,500,000 shares during the last quarter. XTX Topco Ltd raised its position in shares of Unicycive Therapeutics by 142.2% during the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock valued at $136,000 after buying an additional 100,679 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after acquiring an additional 122,089 shares during the last quarter. Finally, Virtu Financial LLC grew its position in Unicycive Therapeutics by 566.8% in the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after acquiring an additional 62,881 shares in the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY remained flat at $0.64 during mid-day trading on Friday. 228,815 shares of the company traded hands, compared to its average volume of 1,455,506. The stock has a market cap of $76.61 million, a PE ratio of -0.66 and a beta of 2.15. Unicycive Therapeutics, Inc. has a one year low of $0.20 and a one year high of $1.29. The stock has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.59.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). Research analysts predict that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on UNCY shares. Guggenheim began coverage on Unicycive Therapeutics in a research report on Monday. They set a "buy" rating and a $6.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $7.50 price target on shares of Unicycive Therapeutics in a report on Friday, April 11th.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.